Top Markets
Coin of the day
Structure Therapeutics Inc. Structure Therapeutics Inc.

Structure Therapeutics Inc.

GPCR
Rank in Stocks #5255
Structure Therapeutics Inc., an international biopharmaceutical company... Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
Share Price
$49.68
Last synced: 2026-08-26
Market Cap
$2.86B
Change (1 day)
-0.48%
Change (1 year)
161.47%
Country
US
Trade Structure Therapeutics Inc. (GPCR)

Category

Stock price history for Structure Therapeutics Inc. (GPCR)
Highest end of day price: $52.30 on 2026-08-01

Lowest end of day price: $23.60 on 2023-02-01
Stock price history of Structure Therapeutics Inc. from 2023 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) -18.19%
2025 90.66%
2024 -37.07%
2023 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$549.38 41.20%
US
$1.05K 47.75%
NL
$148.35 491.02%
US
$122.41 -12.81%
AU
$764.47 7.08%
CH